Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Rigel Pharmaceuticals
RIGL
Rigel Pharmaceuticals
Regulatory Crackdowns And Pipeline Weakness Will Dominate Future Challenges
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
18 Jul 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$23.00
71.8% overvalued
intrinsic discount
09 Aug
US$39.51
Loading
1Y
226.3%
7D
24.6%
Author's Valuation
US$23.0
71.8% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$23.0
71.8% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-93m
268m
2014
2017
2020
2023
2025
2026
2028
Revenue US$260.8m
Earnings US$34.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.48%
Biotech revenue growth rate
12.85%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$34.04m
Earnings '28
x
15.64x
PE Ratio '28
=
US$532.38m
Market Cap '28
US$532.38m
Market Cap '28
/
19.00m
No. shares '28
=
US$28.01
Share Price '28
US$28.01
Share Price '28
Discounted to 2025 @ 6.80% p.a.
=
US$22.99
Fair Value '25
